LNTH vs NNOX vs CBLL Stock Comparison

Lantheus Holdings, Nano-X Imaging and Ceribell Prices as of Oct 27, 2026 Peers: Industry group
LNTH Lantheus Holdings, Inc.
$100.15 +0.4% 1M +72.3% 1Y
Market cap
$6.52B
P/E
23.7x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
7 wins
NNOX Nano-X Imaging Ltd.
$0.32 -50.0% 1M -92.1% 1Y
Market cap
$20.85M
P/E
–
Revenue (TTM)
$15.63M
Div. yield
–
Diagnostic Equipment Healthcare
CBLL Ceribell, Inc.
$27.22 +14.9% 1M +111.2% 1Y
Market cap
$1.04B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

9 decided of 12

Lantheus Holdings leads on 7 of the 12 questions below (Lantheus Holdings 7, Ceribell 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionLNTHNNOXCBLLLeader
Larger companyMarket capitalisation $6.52B $20.85M $1.04B LNTH
Cheaper on earningsLower P/E, profitable companies only 23.7x -0.2x -15.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 17.4x — — –
Faster revenue growthRevenue growth, trailing twelve months +2.3% +31.5% +31.7% CBLL
More profitableNet margin, trailing twelve months 17.7% -747.2% -64.7% LNTH
Better return on capitalReturn on invested capital 12.5% -116.9% — LNTH
Less leveragedLower net debt / EBITDA -0.1x 0.3x 1.6x LNTH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +72.3% -92.1% +111.2% CBLL
Better 5-year returnAnnualised price return, 5 years +34.4%/yr -57.4%/yr — LNTH
Less volatileAnnualised volatility, 1 year 32.3% 105.8% 52.1% LNTH
Higher overall scoreMean of the five percentile scores vs peers 80/100 36/100 38/100 LNTH

Percentile Scorecard

LNTHNNOXCBLL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisLNTHNNOXCBLL
Valuation 80 #46 of 227 54 #105 of 227 22 #178 of 227
Growth 63 #82 of 219 10 #198 of 219 22 #172 of 219
Profitability 94 #13 of 206 10 #185 of 206 38 #129 of 206
Financial Health 69 #74 of 238 71 #71 of 238 81 #46 of 238
Shareholder Returns 93 #11 of 134 – 30 #94 of 134
Overall 80 36 38
  • LNTH ranked among 247 companies in Medical Devices and Diagnostics
  • NNOX ranked among 247 companies in Medical Devices and Diagnostics
  • CBLL ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodLNTHNNOXCBLLSPY
1 month +0.4%-50.0%+14.9% -0.2%
3 months -2.4%-63.6%+52.7% +3.9%
6 months +19.9%-82.2%+30.9% +8.2%
Year to date +50.5%-88.6%+24.1% +12.9%
1 year +72.3%-92.1%+111.2% +12.3%
3 years +49.9%-93.6%— +87.4%
3 years, per year +14.4%-60.1%— +23.3%
5 years +337.5%-98.6%— +67.9%
5 years, per year +34.4%-57.4%— +10.9%
10 years +1,092.3%—— +261.1%
10 years, per year +28.1%—— +13.7%

Risk

MeasureLNTHNNOXCBLLSPY
Volatility, 1Y 32.3%105.8%52.1% 12.7%
Downside volatility, 1Y 27.5%116.3%49.5% 12.7%
Beta vs S&P 500, 1Y 0.591.361.21 1.00
Return / volatility, 1Y 2.24-0.872.13 0.97
Max drawdown, 5Y -59.5%-98.8%-63.9% -25.4%
From 52-week high -9.7%-93.0%-1.7% -1.2%
52-week high $110.94$4.55$27.68 $779.14
52-week low $50.69$0.32$10.92 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleLNTHNNOXCBLL
P/E now vs peer median 23.7xmedian 29.6x -0.2xmedian 29.6x -15.7xmedian 29.6x
P/S now vs peer median 4.2xmedian 2.9x 1.4xmedian 2.9x 10.2xmedian 2.9x
EV/EBITDA now vs peer median 16.5xmedian 17.4x 0.1xmedian 17.4x -13.6xmedian 17.4x
P/FCF now vs peer median 16.9xmedian 22.3x -0.4xmedian 22.3x -19.0xmedian 22.3x
P/B now vs peer median 5.0xmedian 2.3x 0.3xmedian 2.3x 8.1xmedian 2.3x
PEG now vs peer median 0.22median 1.04 -0.08median 1.04 —median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsLNTHNNOXCBLL
Revenue $1.56B $15.63M $101.96M
Gross profit $936.02M -$52.76M $90.65M
Operating income $302.34M -$119.69M -$69.97M
Net income $275.31M -$116.81M -$66.00M
Free cash flow $387.83M -$52.09M -$54.72M
R&D $173.09M $18.93M $22.95M
EPS (diluted) $4.08 $-1.80 $-1.74
Cash & equivalents $593.30M $31.02M $32.66M
Total debt $571.05M $12.50M $19.98M
Shares (diluted) 67.52M 64.79M 38.03M
Enterprise value $4.69B -$158.82M $444.59M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricLNTHNNOXCBLL
P/E 23.7x -0.2x -15.7x
P/FCF 16.9x -0.4x -19.0x
P/Operating cash flow 15.8x -0.5x -19.3x
P/S 4.2x 1.4x 10.2x
P/B 5.0x 0.3x 8.1x
P/Tangible book 10.5x 0.4x 8.1x
EV/EBITDA 16.5x 0.1x -13.6x
EV/EBIT 21.5x 0.0x -13.3x
EV/Revenue 4.2x -0.4x 9.1x
EV/FCF 16.8x 0.1x -17.0x
EV/Operating cash flow 15.8x 0.1x -17.2x
PEG (3Y EPS CAGR) 0.22 -0.08 –

Growth

14 metrics
MetricLNTHNNOXCBLL
Revenue growth (1Y) 2.3% 31.5% 31.7%
Revenue CAGR (3Y) 11.4% 17.7% –
Gross profit growth (1Y) -3.4% -340.0% 33.4%
Gross profit CAGR (3Y) 16.3% -101.8% –
Operating income growth (1Y) -30.9% -107.4% -34.6%
Operating income CAGR (3Y) 118.8% -5.0% –
Net income growth (1Y) 1.6% -109.9% -33.6%
Net income CAGR (3Y) 102.1% -4.9% –
EPS growth (1Y) 5.8% -90.0% -27.5%
EPS CAGR (3Y) 105.5% 2.3% –
Operating cash flow growth (1Y) -21.7% -21.9% -44.3%
Operating cash flow CAGR (3Y) 14.5% -2.7% –
Free cash flow growth (1Y) -10.1% -19.4% -41.8%
Free cash flow CAGR (3Y) 103.0% 1.3% –

Profitability

14 metrics
MetricLNTHNNOXCBLL
Gross margin 60.1% -337.5% 88.9%
EBITDA margin 25.4% -692.4% -67.1%
Operating margin 19.4% -765.6% -68.6%
Pretax margin 23.3% -758.5% -64.7%
Net margin 17.7% -747.2% -64.7%
FCF margin 24.9% -333.2% -53.7%
Operating cash flow margin 26.5% -298.7% -53.0%
Return on equity 21.8% -117.5% -49.0%
Return on assets 11.6% -98.6% -38.3%
Return on invested capital 12.5% -116.9% –
Return on capital employed 14.8% -114.2% -45.1%
Asset turnover 0.7x 0.1x 0.6x
Cash conversion (OCF / net income) 1.5x 0.4x 0.8x
Stock comp / revenue 5.0% 34.9% 16.1%

Financial Health

11 metrics
MetricLNTHNNOXCBLL
Debt / assets 23.6% 3.3% 12.0%
Debt / equity 0.4x 0.0x 0.2x
Net debt / EBITDA -0.1x 0.3x 1.6x
Debt / FCF 1.5x -0.1x -0.4x
Liabilities / assets 45.7% 20.5% 22.9%
Equity / assets 54.3% 79.5% 77.1%
Interest coverage 15.3x – -38.6x
Current ratio 3.1x 2.8x 9.2x
Quick ratio 2.8x 2.4x 8.6x
Cash ratio 1.8x 2.3x 7.5x
Altman Z-score 5.46 -11.07 14.47

Shareholder Returns

7 metrics
MetricLNTHNNOXCBLL
Dividend yield – – –
Net buyback yield 2.9% – -0.6%
Shareholder yield 2.9% – -0.6%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusLNTHNNOXCBLL
Forward P/E 17.4xFY2026 – –
EPS, next fiscal year $5.76FY2026 $-1.31FY2026 $-1.86FY2026
EPS growth, next FY -5.3%FY2026 – –
EPS growth, the year after +4.2% – –
Revenue, next fiscal year $1.57BFY2026 $18.64MFY2026 $118.32MFY2026
Revenue growth, next FY +1.8%FY2026 +43.2%FY2026 +32.9%FY2026
Revenue growth, the year after +12.7% +59.6% +21.1%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersLNTHNNOXCBLL
Held by institutions 100.0% 14.9% 79.9%
Institutions holding 465 102 124
Change in shares held, QoQ +3.4% -46.0% +2.2%
Institutions buying 248 55 74
Institutions selling 142 28 36
Buyers to sellers 1.75 1.96 2.06

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

LNTHNNOXCBLL
LNTH 1.00 0.05 0.21
NNOX 0.05 1.00 0.14
CBLL 0.21 0.14 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, LNTH, NNOX and CBLL?

Lantheus Holdings (LNTH) is the largest by market capitalisation: Lantheus Holdings (LNTH) $6.52B, Nano-X Imaging (NNOX) $20.85M, Ceribell (CBLL) $1.04B.

Which company is growing faster?

Ceribell (CBLL) grew revenue fastest over the trailing twelve months: Lantheus Holdings (LNTH) +2.3%, Nano-X Imaging (NNOX) +31.5%, Ceribell (CBLL) +31.7%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (Lantheus Holdings (LNTH) 17.7%, Nano-X Imaging (NNOX) -747.2%, Ceribell (CBLL) -64.7%). On return on invested capital, Lantheus Holdings (LNTH) leads (Lantheus Holdings (LNTH) 12.5%, Nano-X Imaging (NNOX) -116.9%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Lantheus Holdings (LNTH) +72.3%, Nano-X Imaging (NNOX) -92.1%, Ceribell (CBLL) +111.2%. Over five years, Lantheus Holdings (LNTH) compounded fastest (Lantheus Holdings (LNTH) +34.4%/yr, Nano-X Imaging (NNOX) -57.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (Lantheus Holdings (LNTH) 32.3%, Nano-X Imaging (NNOX) 105.8%, Ceribell (CBLL) 52.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, LNTH, NNOX and CBLL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.